The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Open accessAbstract
OBJECTIVE: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD). METHODS: From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). β-Amyloid (Aβ) deposition in 9 brain regions was examined with [18F]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study. RESULTS: The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF Aβ42/t-tau and Aβ42/p-tau performed better than CSF Aβ42 and Aβ42/40 (AUC difference 0.03-0.12, p<0.05). Using nonoptimized cutoffs, CSF Aβ42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately. CONCLUSIONS: Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global Aβ deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Discordances between imaging and CSF biomarkers may occur [36,41,116–119].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [117]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The continuous relationship between CSF Aβ42 and amyloid PET, however, is “L-shaped” rather than linear [116,117,120].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationpROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citation
Cited by
Sorted by citations
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“The continuous relationship between CSF Aβ42 and amyloid PET, however, is “L-shaped” rather than linear [116,117,120].”
Self-citationCurrent understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationPalmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationTau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Self-citationA multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationSpread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
Vogel, J. W., Iturria‐Medina, Y., Strandberg, O. T., Smith, R. A., Levitis, E., Evans, A. C., Hansson, O., Initiative, A. D. N., Weiner, M. W., Aisen, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15701-2 · Cited by 537
Self-citationCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationPlasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502
Self-citationCSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Self-citationPalmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
Self-citationDeveloping the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 351
Self-citationThe complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 343
Aducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316
Self-citationLiss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Self-citationAPOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
Self-citationCerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284
Self-citationAssociation of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings
O’Bryhim, B. E., Apte, R. S., Kung, N. H., Coble, D. W., & Stavern, G. P. V. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3556 · Cited by 253
Sharma, R. A., Varga, A. W., Bubu, O. M., Pirraglia, E., Kam, K., Parekh, A., Wohlleber, M. E., Miller, M. D., Andrade, A. G., Lewis, C., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0704oc · Cited by 259
Self-citationAdvances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Aducanumab: Appropriate Use Recommendations Update
Cummings, J. L., Rabinovici, G. D., Atri, A., Aisen, P. S. S., Apostolova, L. G., Hendrix, S. B., Sabbagh, M. N., Selkoe, D. J., Weiner, M. W., & Salloway, S. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.34 · Cited by 204
Self-citationCentiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195
Self-citationParnetti, L., Chipi, E., Salvadori, N., D’Andrea, K., & Eusebi, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0459-7 · Cited by 206
Wang, Y., Wu, S., Li, Q., Sun, H., & Wang, H. (2023) · Advanced Science · doi:10.1002/advs.202300325 · Cited by 171
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
Li, D., & Mielke, M. M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00164-5 · Cited by 147
Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials
Chapman, K. R., Bing‐Canar, H., Alosco, M. L., Steinberg, E. G., Martin, B. M., Chaisson, C. E., Kowall, N. W., Tripodis, Y., & Stern, R. A. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0176-z · Cited by 157
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 154
Cognitive reserve and clinical progression in Alzheimer disease
van Loenhoud, A. C., van der Flier, W. M., Wink, A. M., Dicks, E., Groot, C., Twisk, J. W. R., Barkhof, F., Scheltens, P., Ossenkoppele, R., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007821 · Cited by 159
Janelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147
Self-citationThe Past and the Future of Alzheimer’s Disease Fluid Biomarkers
Blennow, K., & Zetterberg, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170773 · Cited by 154
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Self-citationPlasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
Pereira, J. B., Janelidze, S., Stomrud, E., Palmqvist, S., van Westen, D., Dage, J. L., Mattsson, N., & Hansson, O. (2021) · Brain · doi:10.1093/brain/awab163 · Cited by 147
Self-citationDetermining clinically meaningful decline in preclinical Alzheimer disease
Insel, P. S., Weiner, M., Mackin, R. S., Mormino, E., Lim, Y. Y., Stomrud, E., Palmqvist, S., Masters, C. L., Maruff, P. T., Hansson, O., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007831 · Cited by 128
Self-citationIron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease
Gleason, A. J., & Bush, A. I. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00954-y · Cited by 134
Hlávka, J. P., Mattke, S., & Liu, J. (2018) · RAND Corporation eBooks · doi:10.7249/rr2503 · Cited by 134
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Zarkali, A., Thomas, G. E. C., Zetterberg, H., & Weil, R. S. (2024) · Nature Communications · doi:10.1038/s41467-024-49949-9 · Cited by 131
Self-citationBiomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
van Maurik, I. S., Vos, S. J. B., Bos, I., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Barkhof, F., Frölich, L., Kornhuber, J., Wiltfang, J., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30283-2 · Cited by 131
Self-citationAlzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 123
In vivo retention of 18 F-AV-1451 in corticobasal syndrome
Smith, R., Schöll, M., Widner, H., van Westen, D., Svenningsson, P., Hägerström, D., Ohlsson, T., Jögi, J., Nilsson, C., & Hansson, O. (2017) · Neurology · doi:10.1212/wnl.0000000000004264 · Cited by 117
Self-citationAmyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116
Li, R., Nguyen, T. P., Potter, T. B. H., & Zhang, Y. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.101622 · Cited by 114
Elazab, A., Wang, C., Abdel-Aziz, M. H., Zhang, J., Gu, J. J., Górriz, J. M., Zhang, Y., & Chang, C. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.124780 · Cited by 112
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Meyer, S. D., Schaeverbeke, J. M., Verberk, I. M. W., Gille, B., Schaepdryver, M. D., Luckett, E. S., Gabel, S., Bruffaerts, R., Mauroo, K., Thijssen, E. H., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00728-w · Cited by 102
Gerischer, L. M., Fehlner, A., Köbe, T., Prehn, K., Antonenko, D., Grittner, U., Braun, J., Sack, I., & Flöel, A. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.12.023 · Cited by 101
Early Detection of Alzheimer’s Disease Using Non-invasive Near-Infrared Spectroscopy
Li, R., Rui, G., Chen, W., Li, S., Schulz, P. E., & Zhang, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00366 · Cited by 101
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Mattsson, N., Smith, R. A., Strandberg, O. T., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T. G., Zetterberg, H., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004887 · Cited by 95
Self-citationLehmann, S., Delaby, C., Boursier, G., Catteau, C., Ginestet, N., Tiers, L., Maceski, A. M., Navucet, S., Paquet, C., Dumurgier, J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00138 · Cited by 95
Mattsson, N., Insel, P. S., Donohue, M., Jögi, J., Ossenkoppele, R., Olsson, T., Schöll, M., Smith, R., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.001 · Cited by 92
Self-citationRelationship between amyloid and tau levels and its impact on tau spreading
Doré, V., Krishnadas, N., Bourgeat, P., Huang, K., Li, S., Burnham, S. C., Masters, C. L., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05191-9 · Cited by 93
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Alzheimer’s Disease Biomarkers and Future Decline in Cognitive Normal Older Adults
Dumurgier, J., Hanseeuw, B. J., Hatling, F. B., Judge, K. A., Schultz, A. P., Chhatwal, J. P., Blacker, D., Sperling, R. A., Johnson, K. A., Hyman, B. T., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170511 · Cited by 91
Self-citationMyo-inositol changes precede amyloid pathology and relate toAPOEgenotype in Alzheimer disease
Voevodskaya, O., Sundgren, P. C., Strandberg, O. T., Zetterberg, H., Minthon, L., Blennow, K., Wahlund, L., Westman, E., Hansson, O., For the Swedish BioFINDER study group, et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002672 · Cited by 89
Self-citationMattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Self-citationMattsson, N., Ossenkoppele, R., Smith, R. A., Strandberg, O. T., Ohlsson, T. G., Jögi, J., Palmqvist, S., Stomrud, E., & Hansson, O. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0403-x · Cited by 90
Self-citationPlasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
González‐Ortiz, F., Kirsebom, B., Contador, J., Tanley, J. E., Selnes, P., Gísladóttir, B., Pålhaugen, L., Hemminghyth, M. S., Jarholm, J. A., Skogseth, R. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47286-5 · Cited by 93
Self-citationPuzo, C. J., Labriola, C., Sugarman, M. A., Tripodis, Y., Martin, B. M., Palmisano, J. N., Steinberg, E. G., Stein, T. D., Kowall, N. W., McKee, A. C., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0521-0 · Cited by 85
Self-citationStatistical Disease Progression Modeling in Alzheimer Disease
Rakêt, L. L., & Initiative, F. T. A. D. N. (2020) · Frontiers in Big Data · doi:10.3389/fdata.2020.00024 · Cited by 78
Self-citationApplying the ATN scheme in a memory clinic population
Altomare, D., de Wilde, A., Ossenkoppele, R., Pelkmans, W., Bouwman, F. H., Groot, C., van Maurik, I. S., Zwan, M. D., Yaqub, M. M., Barkhof, F., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008361 · Cited by 81
Vanderstichele, H., Janelidze, S., Demeyer, L., Coart, E., Stoops, E., Herbst, V., Mauroo, K., Brix, B., & Hansson, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160286 · Cited by 80
Self-citationPlasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease
Lövheim, H., Elgh, F., Johansson, A. S., Zetterberg, H., Blennow, K., Hallmans, G., & Eriksson, S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.004 · Cited by 82
Self-citationElecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey‐Smith, S. R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00595-5 · Cited by 81
Alosco, M. L., Sugarman, M. A., Besser, L. M., Tripodis, Y., Martin, B. M., Palmisano, J. N., Kowall, N. W., Au, R., Mez, J., DeCarli, C. S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180017 · Cited by 76
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Self-citationWu, X., Piña-Crespo, J., Zhang, Y., Chen, X., & Xu, H. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 82
Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Antelmi, L., Bagnoli, C., David Bartrés-faz, A., Cordone, S., Didic, M., Farotti, L., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12482 · Cited by 76
Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies
Respondek, G., Grimm, M., Piot, I., Arzberger, T., Compta, Y., Englund, E. M., Ferguson, L. W., Gelpí, E., Roeber, S., Giese, A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27872 · Cited by 79
Self-citationChapleau, M., Joie, R. L., Yong, K. X. X., Agosta, F., Allen, I. E., Apostolova, L. G., Best, J., Boon, B. D. C., Crutch, S. J., Filippi, M., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00414-3 · Cited by 73
Self-citationZeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 79
Self-citationLacsogram: A New EEG Tool to Diagnose Alzheimer's Disease
Rodrigues, P. M., Bispo, B. C., Garrett, C., Alves, D., Teixeira, J. P., & Freitas, D. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3069789 · Cited by 69
Amft, M., Ortner, M., Eichenlaub, U., Goldhardt, O., Diehl‐Schmid, J., Hedderich, D. M., Yakushev, I. Y., & Grimmer, T. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01003-w · Cited by 69
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Self-citationSanchez, E., Wilkinson, T., Coughlan, G., Mirza, S., Baril, A., Ramirez, J., Binns, M. A., Black, S. E., Borrie, M., Dilliott, A. A., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13560 · Cited by 62
Self-citationHahn, A., Strandberg, T. O., Stomrud, E., Nilsson, M., van Westen, D., Palmqvist, S., Ossenkoppele, R., & Hansson, O. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz020 · Cited by 61
Self-citationChhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60
Self-citationDiagnosis of Alzheimer's disease via optimized lightweight convolution-attention and structural MRI
Khatri, U., & Kwon, G. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108116 · Cited by 67
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s diseasePreprint
Vogel, J. W., Iturria‐Medina, Y., Strandberg, O. T., Smith, R. A., Evans, A. C., Hansson, O., & for the Alzheimer’s Disease Neuroimaging Initiative, A. T. S. B. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/555821 · Cited by 64
Self-citationVergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3053 · Cited by 59
Self-citationClassification accuracy of TMS for the diagnosis of Mild Cognitive Impairment.
Benussi, A., Grassi, M., Palluzzi, F., Cantoni, V., Cotelli, M. S., Premi, E., Lorenzo, F., Pellicciari, M., Ranieri, F., Musumeci, G., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.01.004 · Cited by 55
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Self-citationModeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Hahn, A., Schain, M., Erlandsson, M., Sjölin, P., James, G. M., Strandberg, O. T., Hägerström, D., Lanzenberger, R. R., Jögi, J., Olsson, T. G., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174508 · Cited by 57
Self-citationBlennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 61
Self-citationLehmann, S., Gabelle, A., Duchiron, M., Busto, G. U., Morchikh, M., Delaby, C., Hirtz, C., Mondésert, E., Cristol, J., Barnier-Figue, G., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105805 · Cited by 58
Ding, M., Ding, S., Du, D., Wang, X., Hu, X., Guan, P., Lyu, Z., & Lin, Y. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117087 · Cited by 56
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
Henriques, A. D., Benedet, A. L., Camargos, E. F., Rosa‐Neto, P., & Nóbrega, O. D. T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.01.002 · Cited by 56
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
de Wilde, A., Reimand, J., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., Bouwman, F. H., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0532-x · Cited by 54
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 56
Ciou, S.-H., Hsieh, A.-H., Lin, Y.-X., Sei, J.-L., Govindasamy, M., Kuo, C., & Huang, C. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115174 · Cited by 52
Vos, A. D., Struyfs, H., Jacobs, D., Fransén, E., Klewansky, T., Roeck, E. E. D., Robberecht, C., Broeckhoven, C. V., Duyckaerts, C. J., Engelborghs, S., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160227 · Cited by 54
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 55
A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment
Kim, S. E., Woo, S., Kim, S. W., Chin, J., Kim, H. J., Lee, B. I., Park, J., Park, K. W., Kang, D., Noh, Y., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180048 · Cited by 46
Arendash, G. W., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L. R., Andel, R., Lin, X., Zhang, X., Wittwer, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190367 · Cited by 52
Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024) · Brain · doi:10.1093/brain/awad361 · Cited by 47
Metadata
- Authors
- Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., Hansson, O., Minthon, L., Toresson, H., Nägga, K., Palmqvist, S., Stomrud, E., Johansson, P., Nilsson, C., Nilsson, M., Mattsson, N., Lindqvist, D., Vestberg, S., Janelidze, S., Zetterberg, H., Blennow, K., Andreasson, U., van Westen, D., Lätt, J., Mannfolk, P., Nilsson, M., Strandberg, O., Sundgren, P., Ståhlberg, F., Lindberg, O., Westman, E., Wahlund, L.-O., Wollmer, P., Smith, R., Olsson, T., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., Beckett, L., Green, R. C., Gamst, A., Saykin, A. J., Morris, J., Potter, W. Z., Green, R. C., Montine, T., Petersen, R., Aisen, P., Gamst, A., Thomas, R. G., Donohue, M., Walter, S., Jack, C. R., Dale, A., Bernstein, M., Felmlee, J., Fox, N., Thompson, P., Schuff, N., Alexander, G., DeCarli, C., Jagust, W., Bandy, D., Koeppe, R. A., Foster, N., Reiman, E. M., Chen, K., Mathis, C., Morris, J., Cairns, N. J., Taylor-Reinwald, L., Trojanowki, J. Q., Shaw, L., Lee, V. M.-Y., Korecka, M., Toga, A. W., Crawford, K., Neu, S., Beckett, L., Harvey, D., Gamst, A., Kornak, J., Saykin, A. J., Foroud, T. M., Potkin, S., Shen, L., Kachaturian, Z., Frank, R., Snyder, P. J., Molchan, S., Kaye, J., Dolen, S., Quinn, J., Schneider, L., Pawluczyk, S., Spann, B. M., Brewer, J., Vanderswag, H., Heidebrink, J. L., Lord, J. L., Petersen, R., Johnson, K., Doody, R. S., Villanueva-Meyer, J., Chowdhury, M., Stern, Y., Honig, L. S., Bell, K. L., Morris, J. C., Mintun, M. A., Schneider, S., Marson, D., Griffith, R., Clark, D., Grossman, H., Tang, C., Marzloff, G., deToledo-Morrell, L., Shah, R. C., Duara, R., Varon, D., Roberts CAN, P., Albert, M. S., Kozauer, N., Zerrate, M., Rusinek, H., de Leon, M. J., De Santi, S. M., Doraiswamy, P. M., Petrella, J. R., Aiello, M., Arnold, S., Karlawish, J. H., Wolk, D., Smith, C. D., Given, C. A., Hardy, P., Lopez, O. L., Oakley, M., Simpson, D. M., Ismail, M. S., Brand, C., Richard, J., Mulnard, R. A., Thai, G., Mc-Adams-Ortiz, C., Diaz-Arrastia, R., Martin-Cook, K., DeVous, M., Levey, A. I., Lah, J. J., Cellar, J. S., Burns, J. M., Anderson, H. S., Laubinger, M. M., Apostolova, L., Silverman, D. H. S., Lu, P. H., Graff-Radford, N. R., Parfitt, F., Johnson, H., Farlow, M., Herring, S., Hake, A. M., van Dyck, C. H., MacAvoy, M. G., Benincasa, A. L., Chertkow, H., Bergman, H., Hosein, C., Black, S., Stefanovic, B., Caldwell, C., Robin Hsiung, G.-Y., Feldman, H., Assaly, M., Kertesz, A., Rogers, J., Trost, D., Bernick, C., Munic, D., Wu, C.-K., Johnson, N., Mesulam, M., Sadowsky, C., Martinez, W., Villena, T., Turner, R. S., Johnson, K., Reynolds, B., Sperling, R. A., Rentz, D. M., Johnson, K. A., Rosen, A., Tinklenberg, J., Ashford, W., Sabbagh, M., Connor, D., Jacobson, S., Killiany, R., Norbash, A., Nair, A., Obisesan, T. O., Jayam-Trouth, A., Wang, P., Lerner, A., Hudson, L., Ogrocki, P., DeCarli, C., Fletcher, E., Carmichael, O., Kittur, S., Borrie, M., Lee, T.-Y., Bartha, R., Johnson, S., Asthana, S., Carlsson, C. M., Potkin, S. G., Preda, A., Nguyen, D., Tariot, P., Fleisher, A., Reeder, S., Bates, V., Capote, H., Rainka, M., Hendin, B. A., Scharre, D. W., Kataki, M., Zimmerman, E. A., Celmins, D., Brown, A. D., Pearlson, G., Blank, K., Anderson, K., Saykin, A. J., Santulli, R. B., Englert, J., Williamson, J. D., Sink, K. M., Watkins, F., Ott, B. R., Stopa, E., Tremont, G., Salloway, S., Malloy, P., Correia, S., Rosen, H. J., Mintzer, J., Longmire, C. F., & Spicer, K.
- Affiliations
- Authors' affiliations are provided at the end of the article.
- ORCID
- Nägga, Katarina
- Stomrud, Erik
- Nilsson, Christer
- Lindqvist, Daniel
- Vestberg, Susanna
- Janelidze, Shorena
- van Westen, Danielle
- Lätt, Jimmy
- Nilsson, Markus
- Sundgren, Pia
- Lindberg, Olof
- Westman, Eric
- Wahlund, Lars-Olof
- Wollmer, Per
- Smith, Ruben
- Thomas, Ronald G.
- Donohue, Michael
- Walter, Sarah
- Dale, Anders
- Felmlee, Joel
- Fox, Nick
- Thompson, Paul
- Alexander, Gene
- Koeppe, Robert A.
- Reiman, Eric M.
- Chen, Kewei
- Lee, Virginia M.-Y.
- Korecka, Magdalena
- Crawford, Karen
- Harvey, Danielle
- Kornak, John
- Foroud, Tatiana M.
- Shen, Li
- Frank, Richard
- Snyder, Peter J.
- Kaye, Jeffrey
- Schneider, Lon
- Heidebrink, Judith L.
- Lord, Joanne L.
- Johnson, Kris
- Stern, Yaakov
- Honig, Lawrence S.
- Bell, Karen L.
- Marson, Daniel
- Clark, David
- Tang, Cheuk
- Marzloff, George
- Shah, Raj C.
- Duara, Ranjan
- Albert, Marilyn S.
- Rusinek, Henry
- de Leon, Mony J
- Doraiswamy, P. Murali
- Petrella, Jeffrey R.
- Karlawish, Jason H.
- Wolk, David
- Smith, Charles D.
- Hardy, Peter
- Ismail, M. Saleem
- Thai, Gaby
- Diaz-Arrastia, Ramon
- DeVous, Michael
- Levey, Allan I.
- Lah, James J.
- Burns, Jeffrey M.
- Apostolova, Liana
- Silverman, Daniel H.S.
- Lu, Po H.
- Johnson, Heather
- Farlow, Martin
- Hake, Ann M.
- van Dyck, Christopher H.
- Chertkow, Howard
- Bergman, Howard
- Black, Sandra
- Stefanovic, Bojana
- Feldman, Howard
- Bernick, Charles
- Johnson, Nancy
- Mesulam, Marsel
- Turner, Raymond Scott
- Sperling, Reisa A.
- Rentz, Dorene M.
- Johnson, Keith A.
- Rosen, Allyson
- Jacobson, Sandra
- Killiany, Ronald
- Norbash, Alexander
- Nair, Anil
- Obisesan, Thomas O.
- Wang, Paul
- Lerner, Alan
- Carmichael, Owen
- Johnson, Sterling
- Asthana, Sanjay
- Carlsson, Cynthia M.
- Preda, Adrian
- Nguyen, Dana
- Tariot, Pierre
- Fleisher, Adam
- Hendin, Barry A.
- Scharre, Douglas W.
- Kataki, Maria
- Pearlson, Godfrey
- Santulli, Robert B.
- Williamson, Jeff D.
- Sink, Kaycee M.
- Ott, Brian R.
- Tremont, Geoffrey
- Salloway, Stephen
- Correia, Stephen
- Rosen, Howard J.
- Mintzer, Jacobo
- Venue
- Neurology
- Published
- 2015-10-06
- Volume
- 85
- Issue
- 14
- Pages
- 1240-1249
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4607601
- OpenAlex
- W2173601762
- Cited by
- 375
- References
- 41
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 46 · 2023: 34 · 2022: 25 · 2021: 38 · 2020: 33 · 2019: 41 · 2018: 36 · 2017: 29 · 2016: 28 · 2015: 1
- FWCI
- 25.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institutes of Health (5u01ag024904-10)
- Canadian Institutes of Health Research
- National Institute on Aging (U01-AG-024904, P50AG005134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, early diagnosis, amyloid PET, cerebrospinal fluid biomarkers, amyloid-beta, tau protein, mild cognitive impairment, 18F-flutemetamol, diagnostic accuracy
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Dementia, Female, Humans, Male, Prospective Studies, Radionuclide Imaging, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review